Bristol Myers Phase 3 Empliciti Study Misses Primary Endpoint
March 09 2020 - 7:43AM
Dow Jones News
By Colin Kellaher
Bristol Myers Squibb Co. Monday said a phase 3 study evaluating
the addition of Empliciti to Revlimid and dexamethasone in newly
diagnosed, untreated multiple myeloma missed its primary
endpoint.
The New York biopharmaceutical company said the combination
didn't show a statistically significant improvement in
progression-free survival compared with Revlimid and dexamethasone
alone in patients with newly diagnosed, previously untreated
multiple myeloma who are transplant ineligible.
Bristol Myers said that while the study didn't meet its primary
endpoint in previously untreated, transplant-ineligible patients
with the blood cancer, the Empliciti, Revlimid and dexamethasone
combination remains a standard treatment for patients with
relapsed/refractory multiple myeloma,
Bristol Myers and AbbVie Inc. are co-developing Empliciti, with
Bristol Myers solely responsible for commercial activities.
Bristol-Myers said it will complete a full evaluation of the
study data and work with investigators to present the results at a
future medical meeting.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
March 09, 2020 07:28 ET (11:28 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
AbbVie (NYSE:ABBV)
Historical Stock Chart
From Mar 2024 to Apr 2024
AbbVie (NYSE:ABBV)
Historical Stock Chart
From Apr 2023 to Apr 2024
